BioVariance GmbH

BioVariance GmbH is a German diagnostics and biomedical data analysis company headquartered in Tirschenreuth, Bavaria. Founded in 2013 by Dr. Josef Scheiber, the company focuses on making biomedical variance quantifiable to improve the treatment of complex diseases such as cancer, infectious diseases, and neurodegenerative disorders. Its interdisciplinary team of data analysts, software developers, chemists, biologists, and management staff works on translational research and AI-based personalized medicine solutions. BioVariance's core mission is to enhance patients' health and quality of life through the analysis and interpretation of medical data. The company aims to extend the lives of patients with complex diseases and simplify their therapy and medication. It has been recognized among the top 100 most innovative medium-sized German enterprises and received the 2021 Global Excellence Award as a leading innovator in AI-based personalized medicine solutions. BioVariance is involved in the EU-funded project BEATsep, which targets the long-term effects of sepsis. The company also conducts studies such as an antibody study and a telomere length study, engaging volunteers for research. With a growing team and newly designed headquarters in Bavaria, BioVariance continues to position itself as a partner in precision medicine and data-driven diagnostics.

BioVariance GmbH was founded in 2013 by Dr. Josef Scheiber, who recognized an opportunity to capture the individually variable effectiveness of medications and use this data to benefit people in need of medical treatment. The company was established in Tirschenreuth, Bavaria, Germany, and has since grown into a team of experts including data analysts, software developers, chemists, biologists, and professional management staff. Over its first decade, BioVariance focused on making biomedical variance quantifiable to improve the treatment of complex diseases. The company's translational research aims to extend the lives of patients with cancer, infectious diseases, and neurodegenerative disorders, and to simplify their therapy and medication. In 2021, BioVariance received the Global Excellence Award as the "Leading innovators in AI based personalized medicine solutions." It has also been recognized among the top 100 most innovative medium-sized German enterprises. BioVariance has participated in the EU-funded project BEATsep, which aims to combat the long-term effects of sepsis. The research consortium BEATsep was established by the Cellular and Molecular Immunoregulation (CMI) research team at the International Clinical Research Centre (ICRC) at St. Anne's University. In 2023, the company conducted an antibody study and subsequently transitioned to a telomere length study, engaging volunteers for research. With newly designed and built headquarters in Tirschenreuth, BioVariance continues to expand its team and mission to improve healthcare through data-driven diagnostics.

• 2023

  Conducted antibody study and transitioned to telomere length study.

• 2021

  Received Global Excellence Award as "Leading innovators in AI based personalized medicine solutions."

• 2013

  BioVariance GmbH founded by Dr. Josef Scheiber in Tirschenreuth, Bavaria.

Leading innovator in AI-based personalized medicine solutions, recognized among top 100 most innovative medium-sized German enterprises.

• AI-based personalized medicine solutions

  Solutions that use artificial intelligence to analyze biomedical data for personalized treatment.

• Biomedical data analysis and interpretation

  Interdisciplinary analysis and interpretation of medical data to improve patient health.

1. 1BioVariance – data-driven diagnosticsbiovariance.com
2. 2Company - BioVariance - data-driven diagnosticsbiovariance.com
3. 3BioVariance GmbH - Wikidatawikidata.org